

December 16, 2020

EudraCT-number: 2015-004503-23

Phase II trial: uPAR PET for preoperative staging of breast cancer patients

Data have been evaluated and primary endpoints (sensitivity and specificity) of uPAR-PET/CT have been evaluated for each of two reader teams – team 1 and team 2. The comparator, US + FNB has also been evaluated. Number of patients in analysis: n=49.

Table: Axillary lymph node staging			
Table 3A	US+FNB	Team 1 uPAR PET/CT	Team 2 uPAR PET/CT
Sensitivity	40.7 (22.4-61.2)	37.0 (19.4-57.6)	29.6 (13.8-50.2)
Specificity	100 (84.5-100)	86.4 (65.1-97.1)	90.9 (70.8-98.9)
Accuracy	67.4 (52.5-80.1)	59.2 (44.2-73.0)	57.1 (42.2-71.2)
Positive Predictive Value	100	76.9 (51.1-91.4)	80.0 (48.6-94.43)
Negative Predictive Value	67.4 (52.46-80.05)	52.8 (44.5-60.9)	51.3 (44.4-58.2)